Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer.
Masuda T, Fujitaka K, Ishikawa N, Nakano K, Yamasaki M, Kitaguchi S, Masuda K, Yamaguchi K, Sakamoto S, Horimasu Y, Kawase S, Miyamoto S, Nakashima T, Iwamoto H, Shiota N, Senoo T, Awaya Y, Kondo T, Yoshida T, Hamada H, Murakami I, Hattori N.
Masuda T, et al. Among authors: murakami i.
J Thorac Dis. 2020 Mar;12(3):1079-1084. doi: 10.21037/jtd.2019.12.46.
J Thorac Dis. 2020.
PMID: 32274176
Free PMC article.